Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.37 USD
+0.02 (1.11%)
Updated Jul 22, 2024 03:59 PM ET
After-Market: $1.37 0.00 (0.00%) 4:22 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ENLV 1.37 +0.02(1.11%)
Will ENLV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ENLV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENLV
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
New Strong Buy Stocks for November 3rd
ENLV: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for October 27th
New Strong Buy Stocks for October 19th
Other News for ENLV
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Enlivex Commences Key Trial for Thumb Osteoarthritis
Enlivex Therapeutics doses first patient in Phase I/II trial of Allocetra
Enlivex Webinar to Discuss Breakthrough Immunotherapy